Tango Therapeutics (TNGX) announced that the first patient has been dosed in the Phase 1/2 trial of TNG462 and Revolution Medicines’ daraxonrasib or zoldonrasib in patients with MTAP-deleted and RAS mutant metastatic pancreatic or lung cancer.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNGX:
- Tango Therapeutics Approves Key Proposals at Annual Meeting
- Biotech Alert: Searches spiking for these stocks today
- Tango Therapeutics announces first patient dosed in TNG456 Phase 1/2 trial
- Tango Therapeutics: Promising Developments and Strategic Focus Justify Buy Rating
- Tango Therapeutics Extends Cash Runway Amid Clinical Progress